Press Releases
Date picker
Category
Results per page
Kancera performs the second partial payment for the Fractalkine project
Regulatory
According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain…
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th September 2017
Regulatory
PERIOD 1 JAN - 30 SEPT 2017 IN BRIEF• R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million…
KANCERA PROVIDES AN OPERATIONAL UPDATE FOR THE ROR PROJECT
Kancera hereby reports that the company's ROR inhibitor KAN0441571 effectively eliminates ROR1-bearing leukemic cells in a mouse model of human chronic lymphocytic leukemia.
Kancera and Recipharm collaborate to manufacture clinical trial supply
Kancera, a development company focused on cancer therapy and Recipharm, a leading contract development and manufacturing organisation (CDMO), have signed a contract for the development and manufacture of the pharmaceutical…
Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567
Kancera today launches the second part of the ongoing clinical Phase I study of KAND567. During this part of the study, KAND567 is administered to groups of healthy subjects in…
INTERIM REPORT FOR KANCERA AB (publ) JANUARI 1ST – JUNE 30TH 2017
This is a translation from the original report published in Swedish August 22nd 2017.
Kancera announces approval for the start of clinical trial of KAND567
The Medical Ethics Committee (METC) at the University Medical Center in Groningen, The Netherlands, has approved the start of clinical Phase I study of KAND567. The first dose to humans…
Kancera has applied for a clinical trial for KAND567
Kancera AB has applied for approval for a Phase I clinical trial. The study is planned to be conducted in collaboration with the clinical contract company QPS in Groningen, The…
Kancera provides an operational update of the PFKFB3 project
Kancera reports that PFKFB3-inhibitor KAN0438757 increases the effect of a promising class of drugs for intractable cancer. Kancera has strengthened their development of drugs directed against PFKFB3 and DNA repair…
Kancera recruits two PhD students to the EU-funded research programme SYNTRAIN
Kancera AB (publ) has previously announced that the company has been awarded a research grant of approximately EUR 500 000, in the context of the EU research programme SYNTRAIN (a…